Targeted Therapy Market Report 2026

The targeted therapy market size has grown strongly in recent years. It will grow from $109.99 billion in 2025 to $118.16 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing global cancer incidence, expansion of oncology research funding, growing adoption of monoclonal antibodies, advancements in molecular biology research, rising approval of targeted cancer drugs.

The targeted therapy market size is expected to see strong growth in the next few years. It will grow to $158.2 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing investments in personalized medicine, growing use of ai-driven drug discovery, expansion of precision diagnostics adoption, rising demand for less toxic cancer therapies, increasing clinical trial activity in oncology. Major trends in the forecast period include increasing development of precision oncology drugs, rising adoption of biomarker-based treatment selection, expansion of combination targeted therapies, growing use of companion diagnostics, enhanced focus on tumor-specific drug design.

The rising prevalence of cancer is expected to drive the growth of the targeted therapy market in the coming years. Cancer refers to conditions in which abnormal cells invade surrounding tissues and divide uncontrollably. Targeted therapy works by blocking the signals that promote cancer cell growth or by triggering cancer cells to self-destruct. It uses medications designed to specifically target genes and proteins that support the survival and proliferation of cancer cells, thereby increasing demand. For example, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases rose to 2,001,140, up from 1,958,310 in 2023, representing a 2.19% increase. Therefore, the growing prevalence of cancer is driving expansion in the targeted therapy market.

Key companies in the targeted therapy market are focusing on strategic partnerships to enhance service offerings and support customers. A strategic partnership is a collaborative arrangement between two or more organizations that enables them to achieve mutual goals. For instance, in September 2023, Shine Technologies, a US-based company producing radioactive isotopes for medical applications, partnered with Curadh MTR Inc., which focuses on advancing molecularly targeted radiation therapies for solid tumors. This partnership aims to leverage radioisotopes to precisely target and eliminate cancer cells, offering patients improved treatment options and advancing the future of cancer therapy.

In November 2025, Johnson & Johnson, a US-based pharmaceutical and consumer healthcare company, acquired Halda Therapeutics for $3.05 billion. Through this acquisition, Johnson & Johnson aims to strengthen its biopharmaceutical pipeline, enhance its protein and peptide engineering capabilities, expand its portfolio of innovative therapeutics, and accelerate the development of next-generation biologics. Halda Therapeutics is a US-based biotechnology company specializing in the design and development of site-specific protein and peptide therapeutics.

Major companies operating in the targeted therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Agilent Technologies Inc., Illumina Inc., Incyte Corporation, Sysmex Corporation, Exact Sciences Corporation, Seagen Inc., Exelixis Inc., Seattle Genetics Inc., Genentech Inc., Daiichi Sankyo Company Limited.

North America was the largest region in the targeted therapy market in 2025. The regions covered in the targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the targeted therapy market by increasing costs of imported biologic raw materials, specialized reagents, laboratory equipment, and biopharmaceutical manufacturing systems. North America and Europe are particularly affected due to dependence on cross-border supply chains for advanced biologics, while Asia-Pacific faces cost pressure on export-oriented drug manufacturing. These tariffs are elevating development and production costs and may slow market entry of new therapies. However, they are also encouraging localized biologics manufacturing, regional research partnerships, and investments in domestic pharmaceutical innovation ecosystems.

The targeted therapy market research report is one of a series of new reports that provides targeted therapy market statistics, including targeted therapy industry global market size, regional shares, competitors with a targeted therapy market share, detailed targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the targeted therapy industry. This targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Targeted therapy is a type of cancer treatment that uses drugs or other substances to attack specific molecules essential for the survival and growth of cancer cells. It works by targeting particular genes and proteins that support cancer cell proliferation.

The main types of targeted therapy include small-molecule drugs and monoclonal antibodies. Small-molecule drugs are synthetic chemicals inspired by or derived from natural products produced by bacteria, fungi, and plants. These therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used to treat cancers such as breast cancer, colorectal cancer, leukemia, lung cancer, lymphoma, renal cancer, and others.

The targeted therapy market includes revenues earned by entities by providing various kinds of cancer drugs, such as EGFR inhibitors, angiogenesis inhibitors, and apoptosis inducers. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.